More stories

  • in

    Tenecteplase Unseats Low-Dose Alteplase Favored for Asian Patients

    Source link : https://newshealth.biz/health-news/tenecteplase-unseats-low-dose-alteplase-favored-for-asian-patients/ T-FLAVOR investigators compared tenecteplase with low-dose alteplase in stroke patients scheduled for endovascular therapy (EVT). The trial notably took place in Japanese patients, believed to be more susceptible to bleeding, for whom low-dose alteplase is still standard of care. More work is needed given concerns that tenecteplase may affect clot migration and distal embolization in […] […] More

  • in

    Non-Operative Treatment for CRC May Include Observation After Complete Response

    Source link : https://newshealth.biz/health-news/non-operative-treatment-for-crc-may-include-observation-after-complete-response/ CHICAGO — Patients who skipped maintenance therapy after a complete response to upfront treatment with a PD-1 inhibitor lived just as long as those who had 3 years of maintenance, data from a cohort study that compared nonsurgical colorectal cancer (CRC) options showed. After more than 3 years of follow-up, patients who entered surveillance had […] […] More

  • in

    Patients With Tardive Dyskinesia Symptoms May Go Undiagnosed

    Source link : https://newshealth.biz/health-news/patients-with-tardive-dyskinesia-symptoms-may-go-undiagnosed/ Tardive dyskinesia (TD), a movement disorder that causes involuntary movements often triggered by antipsychotic exposure, has appeared in the DSM for decades. Despite advancements in diagnostic tools and treatments, TD still goes unrecognized in many cases. “Tardive dyskinesia continues to be a prevalent and clinically significant condition, particularly among older adults, women, and long-term antipsychotic […] […] More

  • in

    Obesity With a Normal BMI? Study Suggests It’s Common

    Source link : https://newshealth.biz/health-news/obesity-with-a-normal-bmi-study-suggests-its-common/ Over 26% of U.S. adults with a normal BMI met new criteria for clinical obesity proposed by the Lancet commission. About 78% of adults had excess adiposity if defined by using two or three abnormal body measurements. Researchers called for studies to determine whether screening with the new obesity framework actually improves downstream health outcomes. […] […] More

  • in

    Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer

    Source link : https://newshealth.biz/health-news/targeted-combo-boosts-pfs-in-braf-mutant-metastatic-colorectal-cancer/ CHICAGO — Adding encorafenib (Braftovi) and cetuximab (Erbitux) to FOLFIRI chemotherapy significantly improved progression-free survival (PFS) as first-line treatment of BRAF V600E-mutated metastatic colorectal cancer, according to secondary analysis of a randomized trial. Results from cohort 3 of the BREAKWATER trial showed that adding the two targeted therapies to FOLFIRI (leucovorin, fluorouracil, and irinotecan) chemotherapy […] […] More

  • in

    FDA Approves Cefepime-Zidebactam for Complicated UTIs

    Source link : https://newshealth.biz/health-news/fda-approves-cefepime-zidebactam-for-complicated-utis/ The novel IV antibiotic combination works ‘synergistically’ to combat gram-negative pathogens in complicated UTIs and pyelonephritis. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-approves-cefepime-zidebactam-complicated-utis-2026a1000i8a?src=rss Author : Publish date : 2026-06-01 19:55:00 Copyright for syndicated content belongs to the linked Source. The post FDA Approves Cefepime-Zidebactam for Complicated UTIs first appeared on News Health. —- Author : News […] More

  • in

    The Pro-Life Movement’s Cruelty Problem

    Source link : https://newshealth.biz/health-news/the-pro-life-movements-cruelty-problem/ She stays quiet because of her child, my patient tells me. But despite her passivity, her husband always manages to find something wrong with her. He shouts at ungodly volumes, threatening, “Don’t make me do something to you that I’ll regret!” Another time, “You’re making me angry enough to hit you!” She invariably cowers in […] […] More

  • in

    FDA Approves Oral Antiviral to Prevent COVID-19 After Exposure

    Source link : https://newshealth.biz/health-news/fda-approves-oral-antiviral-to-prevent-covid-19-after-exposure/ The FDA approved the oral antiviral agent ensitrelvir (Xocova) to help prevent COVID-19 in people ages 12 years or older who were exposed to the SARS-CoV-2 virus, drugmaker Shionogi announced. Ensitrelvir is a SARS-CoV-2 main protease inhibitor also approved in Japan as COVID-19 postexposure prophylaxis (PEP) and as a treatment for mild to moderate COVID. […] […] More

  • in

    Discussing Emerging Therapies and Shared Decision-Making in Multiple Myeloma

    Source link : https://newshealth.biz/health-news/discussing-emerging-therapies-and-shared-decision-making-in-multiple-myeloma/ Developed in partnership with the Our Partner In “Beyond Diagnosis: Multiple Myeloma,” Cleveland Clinic hematologist Sandra Mazzoni, DO, and host John Mangels continue their conversations on communicating effectively and empathetically with patients facing a complex, chronic blood cancer. Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, aligning treatment goals, […] […] More

  • in

    U.S. Adult Cigarette Smoking Rate Hits Another All-Time Low

    Source link : https://newshealth.biz/health-news/u-s-adult-cigarette-smoking-rate-hits-another-all-time-low/ The cigarette smoking rate among U.S. adults dropped to another all-time low last year, with one in 11 adults saying they were current smokers, according to new government survey data. Cigarette smoking is a risk factor for lung cancer, heart disease, and stroke, and it’s long been considered the leading cause of preventable death. The […] […] More

  • in

    Saroglitazar Boosts Response Rates in Primary Biliary Cholangitis

    Source link : https://newshealth.biz/health-news/saroglitazar-boosts-response-rates-in-primary-biliary-cholangitis/ Novel saroglitazar significantly improved biochemical response rates in patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodeoxycholic acid or couldn’t tolerate it, according to the EPICS-III randomized clinical trial. Among 148 patients, 56.7% of those randomized to oral saroglitazar (55 of 97) had a biochemical response at 52 weeks compared with […] […] More

  • in

    ‘I’ve requested a full hysterectomy’

    Source link : https://newshealth.biz/health-news/ive-requested-a-full-hysterectomy/ Emma Barnett shares her life-long struggle with endometriosis – a disease affecting one in ten women of reproductive age, which causes excruciating, often debilitating, pain. Source link : https://www.bbc.com/news/videos/cqlpn09kzrko?at_medium=RSS&at_campaign=rss Author : Publish date : 2026-06-01 17:40:00 Copyright for syndicated content belongs to the linked Source. The post ‘I’ve requested a full hysterectomy’ first appeared on News […] More

Load More
Congratulations. You've reached the end of the internet.